Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice.
Identifieur interne : 002D32 ( Main/Exploration ); précédent : 002D31; suivant : 002D33Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice.
Auteurs : RBID : pubmed:16114991English descriptors
- KwdEn :
- Animals, Antimetabolites, Antineoplastic (therapeutic use), Bleomycin (therapeutic use), Body Weight, Carcinoma, Squamous Cell (therapy), Cell Cycle, Cell Line, Tumor, Cell Proliferation, Combined Modality Therapy, DNA (chemistry), Flow Cytometry, Gamma Cameras, Hydrogen-Ion Concentration, Indium Radioisotopes (therapeutic use), Ki-67 Antigen (biosynthesis), Mice, Mice, Nude, Mitosis, Models, Chemical, Neoplasm Transplantation, Radiopharmaceuticals (therapeutic use), Time Factors.
- MESH :
- chemical , biosynthesis : Ki-67 Antigen.
- chemical , chemistry : DNA.
- chemical , therapeutic use : Antimetabolites, Antineoplastic, Bleomycin, Indium Radioisotopes, Radiopharmaceuticals.
- therapy : Carcinoma, Squamous Cell.
- Animals, Body Weight, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Combined Modality Therapy, Flow Cytometry, Gamma Cameras, Hydrogen-Ion Concentration, Mice, Mice, Nude, Mitosis, Models, Chemical, Neoplasm Transplantation, Time Factors.
Abstract
Labeling of bleomycin with Auger-emitter Indium-111 increases cytotoxicity in squamous cell cancer (SCC) cell lines, as we have reported earlier. In this study, we investigated whether (111)In- BLMC is toxic and effective in vivo among SCC-xenografted mice. The influence of (111)InBLMC on the squamous cell carcinoma cell cycle stimulated interest.
DOI: 10.1089/cbr.2005.20.426
PubMed: 16114991
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice.</title><author><name sortKey="J Skel Saari, Hilkka A" uniqKey="J Skel Saari H">Hilkka A Jääskelä-Saari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Central Hospital, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Central Hospital, Helsinki</wicri:regionArea></affiliation></author><author><name sortKey="Grenman, Reidar" uniqKey="Grenman R">Reidar Grénman</name></author><author><name sortKey="Ramsay, Hans A" uniqKey="Ramsay H">Hans A Ramsay</name></author><author><name sortKey="Tarkkanen, Jussi" uniqKey="Tarkkanen J">Jussi Tarkkanen</name></author><author><name sortKey="Paavonen, Timo" uniqKey="Paavonen T">Timo Paavonen</name></author><author><name sortKey="Kairemo, Kalevi J A" uniqKey="Kairemo K">Kalevi J A Kairemo</name></author></titleStmt><publicationStmt><date when="2005">2005</date><idno type="doi">10.1089/cbr.2005.20.426</idno><idno type="RBID">pubmed:16114991</idno><idno type="pmid">16114991</idno><idno type="wicri:Area/Main/Corpus">002E08</idno><idno type="wicri:Area/Main/Curation">002E08</idno><idno type="wicri:Area/Main/Exploration">002D32</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antimetabolites, Antineoplastic (therapeutic use)</term><term>Bleomycin (therapeutic use)</term><term>Body Weight</term><term>Carcinoma, Squamous Cell (therapy)</term><term>Cell Cycle</term><term>Cell Line, Tumor</term><term>Cell Proliferation</term><term>Combined Modality Therapy</term><term>DNA (chemistry)</term><term>Flow Cytometry</term><term>Gamma Cameras</term><term>Hydrogen-Ion Concentration</term><term>Indium Radioisotopes (therapeutic use)</term><term>Ki-67 Antigen (biosynthesis)</term><term>Mice</term><term>Mice, Nude</term><term>Mitosis</term><term>Models, Chemical</term><term>Neoplasm Transplantation</term><term>Radiopharmaceuticals (therapeutic use)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Ki-67 Antigen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>DNA</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Bleomycin</term><term>Indium Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Body Weight</term><term>Cell Cycle</term><term>Cell Line, Tumor</term><term>Cell Proliferation</term><term>Combined Modality Therapy</term><term>Flow Cytometry</term><term>Gamma Cameras</term><term>Hydrogen-Ion Concentration</term><term>Mice</term><term>Mice, Nude</term><term>Mitosis</term><term>Models, Chemical</term><term>Neoplasm Transplantation</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Labeling of bleomycin with Auger-emitter Indium-111 increases cytotoxicity in squamous cell cancer (SCC) cell lines, as we have reported earlier. In this study, we investigated whether (111)In- BLMC is toxic and effective in vivo among SCC-xenografted mice. The influence of (111)InBLMC on the squamous cell carcinoma cell cycle stimulated interest.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16114991</PMID><DateCreated><Year>2005</Year><Month>08</Month><Day>23</Day></DateCreated><DateCompleted><Year>2005</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1084-9785</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cancer biotherapy & radiopharmaceuticals</Title><ISOAbbreviation>Cancer Biother. Radiopharm.</ISOAbbreviation></Journal><ArticleTitle>Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice.</ArticleTitle><Pagination><MedlinePgn>426-35</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Labeling of bleomycin with Auger-emitter Indium-111 increases cytotoxicity in squamous cell cancer (SCC) cell lines, as we have reported earlier. In this study, we investigated whether (111)In- BLMC is toxic and effective in vivo among SCC-xenografted mice. The influence of (111)InBLMC on the squamous cell carcinoma cell cycle stimulated interest.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In an animal experiment, 10 SCC-xenografted mice were used, two for demonstrating targeting in gamma-camera images, eight for intraperitoneally receiving NaCl, BLM, or (111)InBLMC as therapy. After a 2-week follow-up, the tumors were analyzed for proliferation (mitoses, Ki-67). DNA flow cytometric analysis was carried out from tumor samples and three UT-SCC cell lines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Tumors were observed on gamma-camera images in xenografted mice after a (111)InBLMC injection. The UT-SCC-19A-xenografted mouse had a T/non-T uptake of 7.54 at 4 hours after the injection. At the end of the therapeutic trial, the mice were alive. In spite of a small number of animals, our findings indicate that BLM and (111)InBLMC seem to be more effective than NaCl in reducing tumor size. The proliferative activity was strong in BLM and in (111)InBLMC groups, indicating regrowth of the tumors. In DNA analysis, the percentages of cells in the G2/M-phases increased after exposure to BLM and particularly to (111)InBLMC in all three cell lines.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The effect of BLM is preserved after the adding of Auger-emitter In-111. Tumor-seeking (111)InBLMC can be administered safely at tumor-decreasing concentrations in xenograft head and neck cancers. To demonstrate the antitumor effect of (111)InBLMC, the experiments should be extended to include a larger number of mice. BLM, and especially (111)InBLMC, seems to induce alteration in the cell cycle by producing a G2/M block. The verification of the result requires repeated in vitro experiments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jääskelä-Saari</LastName><ForeName>Hilkka A</ForeName><Initials>HA</Initials><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></Author><Author ValidYN="Y"><LastName>Grénman</LastName><ForeName>Reidar</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ramsay</LastName><ForeName>Hans A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Tarkkanen</LastName><ForeName>Jussi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Paavonen</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kairemo</LastName><ForeName>Kalevi J A</ForeName><Initials>KJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>In Vitro</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Biother Radiopharm</MedlineTA><NlmUniqueID>9605408</NlmUniqueID><ISSNLinking>1084-9785</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antimetabolites, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Ki-67 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>11056-06-7</RegistryNumber><NameOfSubstance>Bleomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance>DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Bleomycin</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Body Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Cycle</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">DNA</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Gamma Cameras</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Ki-67 Antigen</DescriptorName><QualifierName MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mitosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Models, Chemical</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2005.20.426</ArticleId><ArticleId IdType="pubmed">16114991</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16114991
|texte= Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16114991" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |